The market will rise in value from $1.26 billion in 2014 to approximately $1.88 billion by 2024, at a moderate CAGR of 4.08%. This increase will be primarily be driven by the launch of long-acting growth hormone biobetters, which are expected to enter the market in 2017 across the seven major countries. Patient compliance with daily growth hormone drugs has been a long-standing issue in the GHD treatment landscape, and is the greatest unmet need. As a consequence, pharmaceutical companies are focusing heavily on developing easier delivery options for patients, leading to therapies which can be administered weekly or bi-weekly. Once available, patients currently refusing to take their daily growth hormone injections are expected to opt for the long-acting drugs.
GlobalData’s OpportunityAnalyzer: Growth Hormone Deficiency – Opportunity Analysis and Forecast to 2024 report provides annualized market revenue, cost of therapy and treatment usage pattern data across the seven major countries.
Key questions answered in the report:
- Overall, the greatest unmet need in the GHD space is the issue with treatment adherence and compliance. There are other prominent unmet needs highlighted by key opinion leaders (KOLs). What are these and will the pipeline drugs fulfil these unmet needs?
- Six pipeline long-acting GH drugs will be launched in the next ten years. How will the sales of existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
- What are the roles of payers in this highly competitive disease space? How does this affect market shares of GH brands, especially in the US? What are the chances of reimbursement for the long-acting drugs in the pipeline?
Are you aware that long-acting biobetters will eventually replace most of the patient shares of currently marketed GH drugs by 2024.. Find out how!